Thus Vemurafenib, an inhibitor of mutant BRAF, might be an interesting effective treatment alternative of the ECD as reported recently in three multisystemic and refractory ECD patients [9]. The gene discussed is BRAF; the disease is familial atrioventricular septal defect.